Use of rate control medication before cardioversion of recent-onset atrial fibrillation or flutter in the emergency department is associated with reduced success rates

Canadian Journal of Emergency Medicine

Volumn 14, Issue 3, 2012, Pages 169-177

  Blecher, Gabriel E ^a   Stiell, Ian G ^a   Rowe, Brian H ^b   Lang, Eddy ^c   Brison, Robert J ^d   Perry, Jeffrey J ^a   Clement, Catherine M ^e   Borgundvaag, Bjug ^f   Langhan, Trevor ^c   Magee, Kirk ^g   Stenstrom, Rob ^h   Birnie, David ^a   Wells, George A ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d QUEEN S UNIVERSITY   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atrial fibrillation; Cardioversion; Rate control

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; PROCAINAMIDE; SOTALOL;

ADULT; AGED; ARTICLE; CANADA; CARDIOVERSION; DRUG EFFICACY; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; SECONDARY ANALYSIS; SINUS RHYTHM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; CANADA; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREMEDICATION; PROCAINAMIDE; PROPAFENONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84862274195     PISSN: 14818035     EISSN: None     Source Type: Journal    
DOI: 10.2310/8000.2012.110591     Document Type: Article

References (25)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995;155:469-73, doi:10.1001/archinte.1995. 00430050045005.
2. Raitt MH, Volgman AS, Zoble RG, et al. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2006;151:390-6, doi:10.1016/j.ahi.2005.03.019. (Pubitemid 43148983)
3. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008;358:2667-77, doi:10.1056/NEJMoa0708789. (Pubitemid 351860859)
4. Stiell IG, Clement CM, Brison RJ, et al. Variation in management of recent-onset atrial fibrillation and flutter among academic hospital emergency departments. Ann Emerg Med, 2011:57: 13-21.
5. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-354, doi:10.1161/CIRCULATIONAHA.106.177292. (Pubitemid 44252297)
6. Blich M, Edoute Y. Electrical cardioversion for persistent or chronic atrial fibrillation: outcome and clinical factors predicting short and long term success rate. Int J Cardiol 2006;107:389-94, doi:10.1016/j.iicard.2005.03.057. (Pubitemid 43287786)
7. Reiffel JA. Cardioversion for atrial fibrillation: treatment options and advances. Pacing Clin Electrophysiol 2009;32:1073-84, doi:10.1111/i.1540-8159. 2009.02441.x.
8. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAte Control versus Electrical cardioversion (RACE) study. Am Heart J 2005;149:1106-11, doi:10.1016/j.ahj.2004. 11.030. (Pubitemid 40848157)
9. Yealy D, Delbridge T. Dysrhythmias. In: Marx J, Hockberger R, Walls R, et al, editors, Rosen's emergency medicine: concepts and clinical practice. 7th ed. Philadelphia: Mosby Elsevier; 2010. p. 984-1024.
10. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965-80, doi: 101002/(SICI) 1097-0258 (19970515) 16:9<965::AID- SIM509>3.0. CO;2-O. (Pubitemid 27198985)
11. Fragakis N, Bikias A, Delithanasis I, et al. Acute betaadrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate. Europace 2009;11:70-4, doi:10.1093/europace/ eun302.
12. Vijayalakshmi K, Whittaker VJ, Sutton A, et al. A randomized trial of prophylactic antiarrhythmic agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion is planned. Am Heart J 2006;151:863.el-e6, doi:10.1016/i.ahi.2005.09.009.
13. Charmer KS, Birchall A, Steeds RP, et al. A randomized placebo-controlled trial of pre-treatment and short-or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004;25:144-50, doi:10.1016/j.ehi.2003.10.020. (Pubitemid 38112153)
14. Ergene U, Ergene O, Cete Y, et al. Predictors of success in the conversion of new-onset atrial fibrillation using oral propafenone. Eur J Emerg Med 1998;5:425-8, doi: 10.1097/00063110-199812 000-00008.
15. Bianconi L, Boccadamo R, Pappalardo A, et al. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-8, doi:10.1016/0002-9149 (89) 90530-4. (Pubitemid 19187668)
16. Joseph AP, Ward MR. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med 2000;36:1-9, doi:10.1067/mem.2000. 107655. (Pubitemid 30641458)
17. Rostagnp C, Bacci F, Paladini B, et al. Predictors of successful at-hqme chemical cardioversion in new-onset atrial fibrillation. Eur J Emerg Med 1994;1:131-5.
18. Stiell IG, Clement CM, Perry JJ, et al. Association of the Ottawa Aggressive Protocol with rapid discharge of emergency department patients with recent-onset atrial fibrillation or flutter. CJEM 2010;12:181-91.
19. Martinez-Marcog FJ, Garcia-Garmendia JL, Ortega-Carpio A, et al. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86:950-3, doi:10.1016/S0002-9149 (00) 01128-0.
20. Tijunelis MA, Herbert ME. Myth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff-Parkinson-White syndrome in the emergency department. CJEM 2005;7:262-5. (Pubitemid 41670449)
21. Hilleman DE, Spinier SA. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy 2002;22:66-74, doi:10.1592/phco.22.1.66.33492. (Pubitemid 34042389)
22. Chevalier P, Durand-Dubief A, Burri H, et al. Amiodarone versus placebo and class Ic drugs for cardioversion of recentonset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003;41:255-62, doi:10.1016/S0735-1097 (02) 02705-5. (Pubitemid 36092194)
23. Letelier LM, Udol K, Ena J, et al. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 2003;163:777-85, doi:10.1001/archinte.163.7.777. (Pubitemid 36438049)
24. Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract 2000;49:1033-46.
25. Thomas SP, Guy D, Wallace E, et al. Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxincontrolled trial. Am Heart J 2004;147:E3, doi:10.1016/S0002-8703 (03) 00526-X.